Ebola Hemorrhagic Fever, www.CDC.gov

Looming Pressure on Pharma as the Spread of Ebola Continues

When will a vaccine become available for Ebola? Killing over 8,000 people in West Africa since last year and still spreading, the need for a prophylactic Ebola vaccine is becoming increasingly important. Companies are racing to bring a safe vaccine to market and with the current pace of the epidemic in Liberia, Sierra Leone and Guinea, the demand for Ebola …

Michael Hanna Vaccinogen cancer vaccine prostate cancer

The Problem with Cancer Vaccines

  You can’t treat a heterogeneous disease with a homogeneous treatment. That was the takeaway message from Vaccinogen’s founder at the World Vaccines Congress Europe Vaccine Nation caught up with Michael Hanna, the founder of Vaccinogen and creator of autologous patient-specific tumour cell vaccine OncoVAX, to discuss why there have been so many high-profile cancer vaccine failures and how this has affected …

Inovio Presents Phase II Clinical Efficacy Data at the 15th World Vaccine Congress

With the 15th World Vaccine Congress on 13 – 15 October in Brussels is just next month I conducted an interview to one of our key speakers, Dr. Niranjan Y. Sardesai (COO, Inovio Pharmaceuticals, Inc.) to give you further insight into his new exciting clinical data and current challenges in developing cancer DNA vaccines.  Dr. Sardesai has broad development and …

Merck Tecemotide Cancer Vaccine Fails Phase II Clinical Trial Goal

Merck’s therapeutic cancer vaccine candidate, tecemotide, has shown no treatment effect in any trial endpoints Merck’s experimental therapeutic cancer vaccine,  in partnership with Oncothyreon,  has recently shown disappointing clinical trial results after the drug failed to meet its primary endpoint, as well as several other secondary endpoints. Many pharmaceutical companies are currently developing therapeutic cancer vaccines, and these are the …

Exclusive vaccine delivery interview with Dr Chantal Pichon, University of Orleans and CNRS

The 15th World Vaccine Congress on 13 – 15 October in Brussels is just a few weeks away and I recently sat down with one of our key speakers, Dr Chantal Pichon (Professor, University of Orleans and CNRS Center for Molecular Biophysics) for a short interview. Dr Pichon will be discussing her research in Histidylated-based nanoparticles for mRNA vaccines delivery. …

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine

Regen BioPharma Advances Towards Breast Cancer Immunotherapy

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine On the 1st of August 2014, Regen BioPharma reported on progress on its therapeutic cancer vaccine dCellVax, which stimulates the immune system of patients to selectively kill tumors. Thomas Ichim, the Chief Scientific Office of Regen BioPharma, said in a statement that ‘we are please to announce …